The AHA today voiced support for several policy changes in the physician fee schedule proposed rule for calendar year 2020 that would promote access to care, public health, quality and regulatory relief. Specifically, AHA applauded the Centers for Medicare & Medicaid Services’ proposals to reverse previously finalized policies for evaluation and management payments that threaten access to care for vulnerable populations; and implement statutorily required payments for opioid treatment programs, a new bundled payment model for certain substance use disorders, and “mostly gradual, flexible” increases to requirements under the Quality Payment Program. It also welcomed the agency’s willingness to review advisory opinion regulations for the physician self-referral law. AHA expressed concern with CMS’s proposed criteria for therapy assistant services; proposal to price Part B injectable and implantable drugs in the opioid treatment program bundle using the average sales price without the legally mandated 6% add-on; and the proposed Value Pathways framework and cost measure changes to the QPP’s Merit-based Incentive Payment System. CMS is accepting comments on the proposed rule through Friday.

Chairperson's File
Public
We’re at a watershed moment in health care, which gives us opportunities to strengthen how we serve patients and communities. Health care leaders must help…
Perspective
Public
This week, more than 1,000 hospital and health system leaders came to Washington, D.C., united by a shared responsibility: to ensure every community has access…
Headline
The AHA April 23 released a blog responding to a report issued April 22 by Paragon Health Institute. The blog highlights how the report relies on a long list…
Chairperson's File
Public
More than 1,000 leaders from hospitals and health systems across the country will gather in Washington, D.C., early next week at the 2026 AHA Annual…
Headline
The AHA will host a webinar April 16 at 1 p.m. ET featuring leaders from CHRISTUS Health and The Urology Group to share how nurse-first triage and smarter…
Headline
The U.S. Court of Appeals for the 5th Circuit April 9 affirmed rulings by a Mississippi district court that rejected requests by Novartis and PhRMA to enjoin…